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The pharmacokinetics and pharmacodynamics of intravenous bumetanide (0.250 mg/kg), alone 
(treatment I) and after probenecid pretreatment (treatment II), were studied in four mongrel 
dogs. Lactated Ringer's solution was administered by vein throughout both treatments at a flow 
rate of 2 ml/min to avoid fluid and electrolyte depletion. Bumetanide and probenecid concentra- 
tions were analyzed by HPLC, sodium by flame phorometry, and creatinine by colorimetry. 
Although the probenecid markedly reduced the plasma and renal clearances of bumetanide, as 
well as the fraction excreted unchanged in the urine, there was no significant difference between 
treatments I and I I  in the 4-hr natriuretic and diuretic responses. However, analysis of the 
dose-response curves between treatments I and I I  showed that sodium excretion was better 
correlated with bumetanide urinary excretion rate than with plasma concentration. The reasons 
for a poor correlation between treatments during the early time periods are discussed. 
KEY WORDS: bumetanide; probenecid; pharmacokinetics; pharmacodynamics; dose- 
response relationship. 
I N T R O D U C T I O N  
Bumetanide (3-n-butylamino-4-phenoxy-5-sulfamoylbenzoic  ac id) is  
a new high-ceiling diuretic which is 4 0 - 6 0  times more potent than 
furosemide on a molecular weight basis (1-3).  The site of bumetanide 
action appears to be the thick ascending limb of the loop of Henle,  where 
it inhibits, solute reabsorption, although inhibition of sodium transport in 
the proximal tubule also occurs to a lesser extent (4-7).  In addition, 
bumetanide has been shown to exert its natriuretic and diuretic effect from 
the luminal surface of the nephron (6). Since bumetanide is highly bound 
to plasma proteins (8,9), access to the kidney lumen is limited through 
glomerular filtration. However,  as a weak organic acid, bumetanide can 
enter the tubular fluid at the pars recta of the proximal tubule via the 
nonspecific organic acid secretory pathway (1,8). 
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Probenecid is a weak organic acid that competes with bumetanide for 
active secretion into the kidney lumen (1,8). This competition can change 
the dose-response relationship of bumetanide by modifying either the total 
amount of diuretic delivered to its active site or the time course of drug 
delivery. Previous studies (10-13) evaluating the effect of probenecid on 
the pharmacodynamics of bumetanide have been limited and conflicting. 
These discrepancies probably reflect the inability of previous investigators 
(10-13) to measure the concentrations of bumetanide in the plasma and 
urine, presumably for the lack of a sensitive and specific assay method. 
Therefore, a rapid, sensitive, and specific high-performance liquid 
chromatographic (HPLC) assay was developed in an attempt to clarify the 
role of probenecid in modifying bumetanide's dose-response relationship. 
E X P E R I M E N T A L  P R O C E D U R E  
Materials  
An aqueous solution dosage form of bumetanide (Hoffmann-La Roche, 
Nutley, N. J., lot A-29), with the aid of 0.4 N NaOH, was prepared 
immediately prior to use. Probenecid capsules (Merck Sharp and Dohme, 
West Point, Pa., lot D2520) were obtained commercially. Probenecid pow- 
der (Merck Sharp and Dohme, Rahway, N.J.) was used as received. All 
other chemicals and solvents were reagent grade or better, as previously 
reported (14). 
Methods  
Four male, mongrel, conditioned, unanesthetized dogs weighing 21.5- 
32.5 kg received 0.250mg/kg of bumetanide alone (treatment I) and 
0.250 mg/kg of bumetanide after probenecid pretreatment (treatment II). 
Each dog fasted the night before and throughout the entire study period. 
Bumetanide was intravenously infused (Harvard Compact Infusion Pump, 
Harvard Apparatus Co., South Natick, Mass.) over a 3-min period with 
the beginning of the infusion being considered as time zero. A 1.0 g dose 
of probenecid (2 tablets• was ingested the night before 
(11:00-11:30p.m.)  and on the study day (60 min prior to bumetanide 
administration). An interval of at least one week elapsed between studies 
and identical lots for each drug were used throughout. 
Heparinized scalp vein needles (E-Z Set-PRN Intermittent Infusion 
Set, The Deseret Co., Sandy, Utah) were placed in each foreleg of the 
dogs, one for administration of bumetanide and replacement fluids and 
one for obtaining blood samples. Blood samples (3 ml) were collected just 
prior to bumetanide dosing (blank) and at 3, 5, 10, 20, 30, 45, 60, 80, 
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100, 120, 150, 180, 210, and 240 rain. Voided urine was collected via an 
indwelling bladder catheter (Swan-Ganz Flow-Directed Monitoring 
Catheter, Model 93-111-7F, American Edwards Laboratories, Santa Ana, 
Calif.) just prior to bumetanide dosing (blank) and at 20, 40, 80, 120, 180, 
and 240 min. The bladder was flushed with 2 x 5 ml of air at the end of 
each urine collection to insure a complete catch. Lactated Ringer's solution 
was administered by vein throughout the entire study period for both 
treatments I and II at a flow rate of 2 ml/min to avoid fluid and electrolyte 
depletion. All 4-hr plasma samples showed normal sodium concentrations. 
Assays  
Plasma and urine samples containing bumetanide, with and without 
probenecid pretreatment, were analyzed by an HPLC method as recently ' 
reported (14). Probenecid concentrations in plasma were simultaneously 
determined with bumetanide concentrations using the same sample prepar- 
ation, instrumentation, and solvent system. However, both probenecid and 
the internal standard acetophenone were measured using ultraviolet detec- 
tion (254 nm) and had retention times in plasma of 8.0 and 4.0rain, 
respectively (Fig. 1). A representative standard curve of probenecid- 
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Fig. 1. Chromatogram for plasma spiked with probenecid and the internal 
standard, acetophenone, using ultraviolet detection (254 nm). 
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range 50-750t~g/ml resulted in the following linear least-squares 
regression equation: Y = O.O03X + 0.011; r 2 = 0.999. Plasma and urine 
samples were measured for sodium with a flame photometer (Model 455, 
Corning Medical and Scientific, Medfield, Mass.), and creatinine was deter- 
mined colorimetrically using a commercial kit (Sigma Chemical Company, 
St. Louis, Mo.). 
C a l c u l a t i o n s  
Plasma concentration-time curves of bumetanide were fitted (equally 
weighted) to the general polyexponential equation for post constant-rate 
infusion data (15): 
Cp= ~ Yie -x" (1) 
i=1 
In Eq. (1), Cp represents the plasma concentration at time t, Yi is the 
coefficient of the ith exponential term for post constant-rate intravenous 
infusion data, and Ai is the exponent of the ith exponential term. The 
values of the coefficients and exponential terms in Eq. (1) were obtained 
using a nonlinear least-squares regression program (personal communica- 
tion, Dr. J. L. Fox, College of Pharmacy, The University of Michigan, Ann 
Arbor, Mich.) and a microcomputer (Apple II Plus Computer, Apple 
Computer Inc., Cupertino, Calif.). Initial estimates were obtained using 
the program RSTRIP (personal communication, Dr. J. L. Fox, College of 
Pharmacy, The University of Michigan, Ann Arbor, Mich.). The number 
of exponents (n) needed for each data set were determined by the applica- 
tion of Akaike's information criterion (16). Since 
Yi = ~ (1-e~ir)ci/(-hiT) (2) 
i = l  
where T is the constant-rate infusion time and Ci is the coefficient of the 
ith exponential term for bolus intravenous data, Eq. (1) can be rearranged 
to the corresponding equation (ref. 15): 
Cp = i (1-e~ir)Cie-~it/(-hiT) (3) 
Once the values of the coefficients and exponential terms in Eq. (1) are 
determined by computer fitting, the values of Ci in Eq. (3) can be calculated. 
The following pharmacokinetic parameters were calculated using stan- 
dard equations (refs. 15, 17): 
V I = D /  ~ Ci (4) 
i = 1  
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i = 1  i = 1  
W d  . . . .  = D / ( h l  ~ Ci/hi) (6) 
i = 1  
CLp = D Cilhi (7) 
i 1 
CLr=Ae~/ i Ci/hi (8) 
i = I  
CL,~r = CLp - CLr (9) 
T1/2 = 0.693/>, 1 (10) 
K~o = CLp/ V~ (11) 
fe = A e ~ / D  (12) 
In Eqs. (4)-(12), V1 is the volume of the central compartment; Vds~ 
is the volume of distribution steady-state; Va . . . .  is that volume which, 
when multiplied by Cp in the log-linear phase, is equal to the amount of 
drug in the body; D is the intravenous dose (equal to the product of the 
zero-order infusion rate and the length of infusion); Ca and hi are the 
coefficient and exponent, respectively, such that M is the smallest of the 
M's of the polyexponential equation; CLv is the total plasma clearance; 
CL, is the renal clearance; CL,~ is the nonrenal clearance; Ae ~ is the 
amount of unchanged drug recovered in the urine at time infinity; TI/2 is 
the biologic half-life; K~0 is the first-order elimination rate constant from 
the central compartment; and fe is the fraction of the available dose excreted 
unchanged in the urine. Creatinine clearance (CLef) was calculated by 
dividing the urinary excretion rate of creatinine by its plasma concentration 
at the midpoint of the urine collection period. 
Data throughout the study are expressed as the means • unless 
otherwise indicated. Statistical differences between treatments I and II 
were determined by a paired t-test. Statistical differences within a specific 
treatment were determined by a single factor analysis of variance and 
Newman-Keuls multiple range test. A p value < 0.05 was considered to be 
significant. 
RESULTS 
Plasma concentrations of bumetanide over 4 hr were fitted to a biex- 
ponential equation for six data sets and to a triexponential equation for 
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Table I. Coefficients and Exponential Terms of Bumetanide Obtained Using Biexponential 
and Triexponential Equations 
Biexponential Equation 
C1 C2 ~1 X2 
Dog Treatment" (ng/ml) (ng/ml) (min -1) (min -1) g 2b C O R R  c 
1 I 120 1855 0 . 0 0 9 5  0.1150 0.991 0.994 
II 309 1342 0 . 0 0 9 9  0.1035 0.999 0.999 
2 I 119 1634 0 . 0 1 0 2  0.1016 0.997 0.998 
II 1023 1245 0 . 0 1 7 5  0.1319 0.999 0.999 
3 I 125 1978 0 . 0 1 2 5  0.1166 0.996 0.997 
4 I 164 1187 0 . 0 1 3 4  0.1265 0.995 0.996 
Triexponential Equation 
C1 C2 C3 ~1 ~2 ~3 
Dog Treatment (ng/ml) (ng/ml) (ng/ml) (min -1) (min -1) (min -1) R 2b C O R R  c 
3 II 406 1115 908 0.0125 0.0655 0.2786 0.999 0.999 
4 II 188 756 1937 0.0074 0.0415 0.1859 0.999 0.999 
"Treatment I represents bumetanide before probenecid pretreatment. Treatment II represents 
bumetanide after probenecid pretreatment. 
b R 2 = [E(Obs)2 _ ,~,(Dev)2]/E(Obs)2. 
CCORR represents the correlation between the calculated and observed plasma concentra- 
tions. 
two data sets (Table I). The goodness of the fit, as determined by R2 and 
C O R R ,  was 0.991 or higher. 
The  pharmacokinet ics  of bumetanide  alone ( treatment I) and after 
probenecid  pre t rea tment  ( t reatment  II), are presented in Table  II. Total  
plasma clearance of bumetanide was significantly reduced after probenecid 
pre t rea tment  (9.654-1.32 for t rea tment  I vs 4 . 6 9 + 0 . 8 0  m l / m i n ,  kg for 
t rea tment  II;  p < 0.01), resulting in significantly higher plasma concentra-  
tions of the diuretic, except for the first 5 min (Fig. 2). The change in total 
plasma clearance was due to the dramatic  reduction (six-fold) in bumetanide 
renal clearance (4.55 4-0.89 for t rea tment  I vs 0 .759+0 .154  m l / m i n ,  kg 
for t rea tment  II;  p < 0.005) since the nonrenal  clearance did not significantly 
differ between treatments.  As a consequence of the reduced renal clearance, 
a .significantly smaller fraction of the bumetanide  dose was excreted 
unchanged in the urine in the presence of probenecid (0.4704- 0.029 for 
t rea tment  I vs 0 .164•  for t rea tment  II;  p < 0.002). This reduction 
in the urinary excretion of bumetanide was observed to occur predominant ly  
during the first 40 min following administration of the diuretic (Fig. 3). 
T1/2 did not change after probenecid pre t rea tment  although K,o was 
significantly reduced. This demonstra tes  the unreliability of biologic half- 
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Fig. 2. Plasma concentration vs time plots of bumetanide 
alone (0------0), bumetanide after probenecid pretreat- 
ment (O-- -  O), and probenecid ([3 [-1). Data are 
expressed as the mean:t:SEM (n =4). Asterisks denote 
statistical differences between treatments I and II. 
upon distributive as well as elimination characteristics of the drug. The 
V d  . . . .  Of bumetanide  was significantly diminished by concomitant  
administration with probenecid while V1 did not change. Vdss showed a 
30% decrease after probenecid pret reatment .  However ,  the change was 
not significant at the 95 % confidence level and probably reflects the limited 
number  of dogs studied (0.10 > p  > 0.05). 
The  effects of probenecid on bumetanide- induced diuresis and 
natriuresis are presented in Table III .  Pharmacodynamic  data are repor ted 
as electrolyte excretion rate and cumulative excretion (as opposed to 
fractional excretion) since sodium concentrations and creatinine clearances 
did not change between t reatments  (CLef = 2.49 + 0.24 for t rea tment  I vs 
2 .20+  0.50 m l / m i n ,  kg for t rea tment  II;  p >0 .20) .  Probenecid pretreat-  
ment  had no significant effect on the cumulative urine volume (1060+ 77 
for t rea tment  I vs 942 + 79 ml /4  hr for t rea tment  II;  p > 0.20), the cumula- 
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Fig. 3. Urinary excretion rate vs midpoint time plots of 
bumetanide alone ( O  0 )  and bumetanide after pro- 
benecid pretreatment ( O  - - - O) .  Data are expressed as the 
mean + S E M  (n  = 4).  Asterisks denote statistical differences 
between treatments I and I I .  
tive sodium excretion (121 • 17 for treatment I vs 116• 11 mEq/4 hr for 
treatment II; p>0 .50) ,  or the time course of bumetanide-induced 
natriuresis (Fig. 4). In addition, Fig. 4 demonstrates that the maximal 
response to intravenous bumetanide occurred approximately 30 rain after 
dosing, indicating a time lag for drug effect. 
DISCUSSION 
Experiments in animals and humans have demonstrated that the critical 
determinant with respect to furosemide's natriuretic and diuretic effect is 
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Table III. Effects of Probenecld on Bumetanide Diuresis and Natriuresis 
Urine volume Sodium excretion 
Dog Treatment a (ml/4 hr) (mEq/4 hr) 
1 I 1131 123 
II 922 105 
2 I 1028 116 
II 984 123 
3 I 967 103 
II 1022 128 
4 I 1115 143 
II 842 107 
Mean I 1060 121 
(SD) (77) (17) 
Mean II 942 116 
(SD) (79) (11) 
Level of significance NS NS 
(p >0.20) (p >0.50) 
aTreatment I represents bumetanide before probenecid pretreatment. Treat- 
ment II represents bumetanide after probenecid pretreatment. 
the drug!s luminal concentration or amount  rather  than its plasma con- 
centration (18-22). The determinants  of bumetanide response are less well 
understood although this new loop diuretic has a pharmacologic action 
similar to that of furosemide. Since 9revious investigators (10-13) did not 
measure  the concentrations of bumetanide  in plasma and urine, they were 
unable to establish a relationship between the pharmacodynamic  response 
of bumetanide  and concentrations of drug in a sampling compar tment  
reflective of its site of action. 
Fr iedman and Roch-Ramel  (10) studied the renal hemodynamic  and 
natriuretic effects of bumetanide  and furosemide in cats. They reported 
that  probenecid (50 mg/kg i .v . )  failed to block the natriuretic effect of 
bumetanide (0 .025/~g/min .  kg) when infused into one renal artery but 
abolished the natriuretic action of furosemide ( 1 . 0 / l g / m i n .  kg). The 
authors (10) proposed two possible mechanisms to explain this finding: 
first, that the renal tubular t ransport  of bumetanide was not interfered with 
by probenecid,  in contrast  to furosemide, due to a greater  affinity of 
bumetanide  for the t ransport  system; and second, that bumetanide  might 
reach its site of action through the peri tubular  membrane .  However ,  Hol-  
land and Williamson (11) subsequently demonstra ted  in dogs that pro-  
benecid pre t rea tment  (50mg/kg i .v . )  could significantly block the 
natriuretic and diuretic actions of bumetanide  (0 .05 / lg /min  9 kg), presum- 
ably by inhibiting its tubular secretion. The reason for the discrepancy 
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Fig, 4. Sodium excretion rate vs midpoint time plots of bumetanide alone (Q--O) and 
bumetanide after probenecid pretreatment (C) - - - C)). Data are expressed as the mean • 
SEM (n = 4). Asterisks denote statistical differences between treatments I and If. 
between these two studies (10,11) is difficult to reconcile since their experi- 
mental designs were similar. Perhaps a species difference exists between 
the cat and dog with respect to their organic acid transport systems. 
Conflicting reports have also appeared in the literature concerning the 
effect of probenecid on bumetanide response in healthy volunteers (12,13). 
In 1975, Lant (12) reported that in two healthy subjects probenecid blocked 
a major part of the excretory responses evoked by 0.5 mg intravenous 
bumetanide. However, the urinary responses to 3 mg bumetanide were 
largely unaltered by this agent. Thus, it appears that at higher doses of 
bumetanide, a sufficient amount of drug can enter the tubular lumen in 
the presence of probenecid to produce an adequate natriuretic response. 
In contrast, Brater and Chennavasin (13) observed that in eight healthy 
subjects, probenecid affected neither the cumulative response nor time 
course of response to 0.5 and 1.0 mg doses of bumetanide. These authors 
(13) ,suggest that probenecid does not affect the renal handling of 
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Fig. 5. Sodium excretion rate vs plasma concentration plots of bumetanide 
alone (O O) and bumetanide after probenecid pretreatment (C)--- C)). 
Data are expressed as the mean • SEM (n = 4). 
bumetanide, although they acknowledge that confirmation of this 
hypothesis requires the measurement  of bumetanide concentrations. 
In the present study, we demonstrated that probenecid does inhibit 
the active secretion of bumetanide into the tubular fluid of dogs, as eviden- 
ced by the dramatic reduction in CLr and re. Despite this inhibition, there 
were no significant differences between treatments I and II in the 4-hr 
natriuretic and diuretic responses. Therefore,  the time course of bumetanide 
in plasma and urine was analyzed with respect to the natriuretic effect in 
an at tempt to define the determinants of bumetanide response. 
Figure 5 shows that probenecid caused a significant shift to the right 
in the relationship between sodium excretion rate and the logarithm of 
bumetanide plasma concentration over the entire dose-response curve. 
This effect is consistent with that of a competitive inhibitor. Furthermore,  
it suggests that higher plasma concentrations of bumetanide are required 
in the presence of probenecid to elicit a natriuretic response equivalent to 
that produced by lower plasma concentrations when probenecid is absent. 
In contrast, sodium excretion rate was found to be better correlated with 
the logarithm of bumetanide urinary excretion rate (Fig. 6). Still, poor  
correlations were observed between treatments I and II during the first 
40 min after bumetanide administration (two highest values for urinary 
excretion rate in each treatment). This finding reflects the following two 
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Fig. 6. Sodium excretion rate vs urinary excretion rate plots of bumetanide  alone 
( O - - - - ~ )  and bumetanide  after probenecid pre t rea tment  ( O - - - O ) .  Data  are 
expressed as the  mean  • SEM (n = 4). 
complications which exist when analyzing the data. First, the present model 
does not accommodate the disequilibrium between the urine concentration 
and effect compartment (biophase) which occurs during the early distribu- 
tion phase (23). Second, bumetanide demonstrates a nonlinear renal clear- 
ance during these early time periods for treatment I only (Fig. 7). 
Although speculative, a mechanism consistent with this change in 
bumetanide renal clearance would be a reduction in tubular reabsorption 
at a location distal to the diuretics site of action. This could account for 
the greater than proportional amount of unchanged drug being excreted 
into the urine during the first 40 rain of treatment I without a concomitant 
increase in bumetanide response. The reason why a nonlinear renal clear- 
ance of bumetanide is not observed during treatment II is unclear. Perhaps 
probenecid interferes with the tubular reabsorption of bumetanide such 
that changes in urine flow and/or pH are not important in affecting the 
diuretics renal clearance. A similar finding with respect to furosemide was 
recently reported by Green and Mirkin (24). They observed that in rats, 
urinary acidification produced a profound decrease in the renal clearance 
of furosemide compared to those animals with a more alkaline urine. 
However, the diuretic response did not differ among the animals despite 
the alteration in furosemide renal clearance. This implies that an equivalent 
amount of furosemide reaches the loop of Henle in both circumstances 
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Fig. 7. Renal clearance vs midpoint time plots of bumetanide alone (O _~) and 
burnetanide after probenecid pretreatment  (O-  - -  O). Data are expressed as the mean • 
SEM (n = 4). Asterisks denote statistical differences within a specific treatment.  
(HCI vs NaHCO3 treated rats). The authors (24) state that the most likely 
mechanism for a decreased renal clearance of furosemide is therefore 
tubular reabsorption from the acidified urine occurring in the distal tubule 
and collecting duct. 
In conclusion, although probenecid caused marked changes in the 
pharmacokinetic parameters of bumetahide (decreased plasma and renal 
clearances, decreased V~,rea and Klo, and decreased fraction excreted 
unchanged in the urine), there was no significant difference between treat- 
ments I and II in the cumulative response or time course of response to 
the diuretic. However, analysis of the dose-response curves between treat- 
ments I and II showed that bumetanide urinary excretion rate was a better 
indicator of natriuresis and diuresis than was the plasma concentration. 
Furthermore, these results support the hypothesis that adequate luminal 
concentrations or amounts of bumetanide are a prerequisite for the drug's 
pharmacodynamic effects. 
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